Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

LaNova of Shanghai Sells Myeloma ADC Candidate to AstraZeneca for $600 Million

publication date: May 15, 2023

Shanghai’s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million (including $55 million upfront) plus royalties on sales. LaNova said LM-305 targets G protein-coupled receptor, class C, group 5, member D (GPRC5D). The candidate consists of an anti-GPRC5D monoclonal antibody, a protease-degradable linker and a cytotoxic payload, monomethyl auristatin E (MMAE). LM-305, which is aimed at multiple myeloma, has IND approvals in the US and China. Founded in 2019, LaNova has four clinical stage oncology candidates and eight pre-clinical molecules in development. More details....

Stock Symbol: (NSDQ: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital